PharmiWeb

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, ...
PharmiWeb

Zealthy Review 2026: How Zealthy Compares to FitRx and RoenRx for Weight Loss & GLP-1 Care

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight management has undergone a seismic shift. Zealthy is one of the fastest-growing telehealth weight-loss platforms in the ...
PharmiWeb

VSee Health, Inc. Announces Postponement of Annual Meeting of Stockholders Until December 30, 2025

SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (NASDAQ:VSEE) a leader in innovative telemedicine solutions, today announced that it anticipates that it will not have a ...
PharmiWeb

Expanded PTFE Market Report 2025: Trends, Forecast and Competitive Analysis to 2031 with Profiles on The Chemours Company, 3M Company, Saint-Gobain, Nitto Denko, Arkema ...

Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offering.The global expanded PTFE market is expected to grow with a CAGR of 6.1% from 2025 to 2031. The ...
PharmiWeb

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the ...
PharmiWeb

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for ...
PharmiWeb

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the year with a calm, almost surgical approach to building out its foundation.
PharmiWeb

NeuraLight Reveals the World-Class Scientific Leaders Helping to Advance Its Transformation of Disease Progression Measurement in Neurology

Precision biomarker company’s Scientific Advisory Board includes multiple Nobel Prize winners and the creators of current gold standard in Parkinson’s disease progressionCAMBRIDGE, Mass., AUSTIN, ...
PharmiWeb

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused.
PharmiWeb

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive B…

ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
PharmiWeb

ZCG-Backed Unimed Acquires Elssi Maritime Services

Acquisition Accelerates Growth Strategy by Adding Elssi’s Specialized Testing Services to Unimed’s Global Comprehensive Maritime Compliance SolutionsNEW YORK--(BUSINESS WIRE)--Universal Maritime ...
PharmiWeb

VSee Health, Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement

SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (Nasdaq:VSEE, VSEEW), a leading provider of telehealth and digital health solutions, today announced that it has regained ...